Open access
Sep 2026
The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their clinical impact is limited by immune-related adverse events (irAEs), therapeutic resistance, and the lack of reliable predictive biomarkers, contributing to a shift from early promise to a therapeutic plateau. irAEs affect multiple organ s...
Joud Hajjar, B. Stephen, A. Aaroe et al.
· Journal of Immunotherapy and... · 1 citation